SCHEMBL1368070

SCHEMBL1368070

COc1cc(OC)c2cc(C(=O)C=Cc3ccc(Cl)cc3Cl)c(=O)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.62
MAOA P21397 8/20 0.62
MAPT P10636 4/20 0.52
NPC1 O15118 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 2/20 0.51
ABCG2 Q9UNQ0 2/20 0.48
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
PTPN5 P54829 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
STAT3 P40763 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
MCL1 Q07820 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368069 1.00 MAOB (0.62) MAOBMAOAMAPTNPC1L3MBTL1
SCHEMBL1368295 1.00 MAOB (0.62) MAOBMAOAMAPTNPC1L3MBTL1
SCHEMBL1367944 0.87 MAOB (0.71) MAOBMAOAMAPTKDM4EABCG2
SCHEMBL1368728 0.87 MAOB (0.71) MAOBMAOAMAPTKDM4EABCG2
SCHEMBL1367942 0.87 MAOB (0.71) MAOBMAOAMAPTKDM4EABCG2
SCHEMBL1369982 0.84 MAOB (0.61) MAOBMAOAMAPTNPC1L3MBTL1
SCHEMBL1369980 0.84 MAOB (0.61) MAOBMAOAMAPTNPC1L3MBTL1
SCHEMBL1368389 0.81 MAOB (0.81) MAOBMAOAMAPTKDM4EABCG2
SCHEMBL1368759 0.81 MAOB (0.81) MAOBMAOAMAPTKDM4EABCG2
SCHEMBL1368391 0.81 MAOB (0.81) MAOBMAOAMAPTKDM4EABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS MAOB 2929/4885MAOA 3570/4885MAPT 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.